<p><span>L</span>-asparaginase is a versatile enzyme that has been a vital tool in both cancer treatment and food production. In the clinic, it’s used as a first-line treatment for acute lymphoblastic leukemia. That’s because it can deplete the extracellular <span>L</span>-asparagine that cancer cells need to multiply. In the food industry, it helps reduce the formation of acrylamide in starchy foods that are cooked at high heat. That makes food safer for consumers. The enzyme’s performance depends heavily on where its genes come from. That source affects how well it works, how stable it is, how likely it is to trigger an immune response-and how feasible it is to produce. To evaluate the best gene sources for <span>L</span>-asparaginase, this review scoured the major biomedical databases. It fills a gap in existing research by systematically assessing gene sources based on their suitability for different applications: cancer therapy, food safety and biosensing. By matching gene selection with the needs of downstream applications, this review shows how application-driven gene sourcing can lead to safer, more effective and more viable <span>L</span>-asparaginase variants. That approach gives us new insights to guide the next generation of biotech and clinical advancements in enzyme design and deployment.</p>